Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sirion’s topical drug found effective in Phase III ocular inflammation trial
The two multi-center studies evaluated the safety and efficacy of Durezol 0.05% compared to placebo dosed twice a day (BID) and four times a day (QID) beginning 24
The two multi-center studies evaluated the safety and efficacy of Durezol 0.05% compared to placebo dosed twice a day (BID) and four times a day (QID) beginning 24
BioChemics has developed a novel, transdermal drug delivery system that for the first time may allow almost any drug to be efficiently delivered through the skin. The transdermal
The agreement is effective March 1, 2008 through 2010. It covers Magnevist in multiple presentations, including five, 10, 15 and 20mL single-dose vials, 50 and 100mL pharmacy bulk
The Phase II trial is a randomized, double blind, placebo controlled trial evaluating high risk geriatric patients following open heart surgery procedures. Patients in the treatment arm received
Kamada’s aerosolized Alpha-1 Antitrypsin product is currently undergoing Phase II clinical trials. David Tsur, CEO of Kamada, said: “This significant recognition grants Kamada various benefits such as research
The initial clinical development of Virulizin under the agreement will be in advanced pancreatic cancer. Under the terms of the agreement, GeneSense will be entitled to receive payments
The patent describes gene sequences, which have already been tested as HIV vaccine candidates in a Phase I clinical trial. Currently, the gene sequences are tested in a
The MITI IV is a Phase II, multicentre, double-blinded, placebo-controlled, ascending-dose clinical trial evaluating the safety of the intravenous administration of microplasmin in 40 patients with acute ischemic
The most important finding in this first Phase II study is that the unique candidate drug BVT.115959 is very safe and tolerable. Moreover, a positive treatment effect that
Combining OSI Pharmaceuticals’s Integrated Lead Discovery platform with BioTrove’s RapidFire mass spectrometry-based assay development, screening and analysis services, the agreement will enable customers to pursue challenging drug targets